269 related articles for article (PubMed ID: 23239103)
1. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis.
Cindolo L; Fanizza C; Romero M; Pirozzi L; Autorino R; Berardinelli F; Schips L
World J Urol; 2013 Jun; 31(3):665-71. PubMed ID: 23239103
[TBL] [Abstract][Full Text] [Related]
2. Clinical effects and economical impact of dutasteride and finasteride therapy in Italian men with LUTS.
Cindolo L; Berardinelli F; Fanizza C; Romero M; Pirozzi L; Tamburro FR; Pellegrini F; Neri F; Pitrelli A; Schips L
Arch Ital Urol Androl; 2013 Dec; 85(4):200-6. PubMed ID: 24399122
[TBL] [Abstract][Full Text] [Related]
3. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
4. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
Issa MM; Runken MC; Grogg AL; Shah MB
Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
[TBL] [Abstract][Full Text] [Related]
5. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF
J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569
[TBL] [Abstract][Full Text] [Related]
6. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
[TBL] [Abstract][Full Text] [Related]
7. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
8. Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?
Pirozzi L; Sountoulides P; Castellan P; Presicce F; Lombardo R; Romero M; De Nunzio C; Tubaro A; Schips L; Cindolo L
Curr Drug Targets; 2015; 16(11):1165-71. PubMed ID: 25981606
[TBL] [Abstract][Full Text] [Related]
9. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
Arena F
Minerva Urol Nefrol; 2013 Sep; 65(3):211-6. PubMed ID: 23872632
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
11. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia.
Zong HT; Peng XX; Yang CC; Zhang Y
Asian J Androl; 2011 Nov; 13(6):812-8. PubMed ID: 21892196
[TBL] [Abstract][Full Text] [Related]
13. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
14. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
15. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
16. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
Fenter TC; Davis EA; Shah MB; Lin PJ
Am J Manag Care; 2008 May; 14(5 Suppl 2):S154-9. PubMed ID: 18611089
[TBL] [Abstract][Full Text] [Related]
17. Finasteride versus dutasteride: a real-world economic evaluation.
Fenter TC; Runken MC; Black L; Eaddy M
Am J Manag Care; 2007 Feb; 13 Suppl 1():S23-8. PubMed ID: 17295602
[TBL] [Abstract][Full Text] [Related]
18. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
[TBL] [Abstract][Full Text] [Related]
19. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
20. Finasteride or dutasteride for the pharmacological treatment for male lower urinary tract symptoms due to benign prostatic hyperplasia?
Alcántara-Montero A; Brenes-Bermúdez FJ
Actas Urol Esp; 2016 May; 40(4):268-9. PubMed ID: 26774534
[No Abstract] [Full Text] [Related]
[Next] [New Search]
